6 results on '"Fallon, M.T."'
Search Results
2. Palliative Care in the Elderly Breast Cancer Patient
- Author
-
Laird, B.J.A. and Fallon, M.T.
- Subjects
- *
CANCER patients , *BREAST cancer , *PALLIATIVE treatment , *THERAPEUTICS , *MEDICAL care for older people - Abstract
Abstract: Breast cancer is most common in the elderly and their needs are distinctly different from their younger counterparts. Although tumoricidal treatment may be given, a palliative approach to disease management will probably occur. Palliative and supportive care is an integral component of the management of the elderly breast cancer patient. Common problems include pain, cognitive impairment, depression, lymphoedema and ulcerating disease. End of life care and dignity therapy are also of great importance. Elderly patients with breast cancer are a unique cohort whose nuances with regard to palliative care issues rightly deserve special consideration. The main issues affecting the elderly breast cancer patient are discussed within this overview. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
3. Morphine, constipation and performance status in advanced cancer patients.
- Author
-
Fallon, M.T.
- Subjects
- *
CONSTIPATION , *MORPHINE , *CANCER pain treatment - Abstract
Studies constipation associated with the use of morphine in treatment of pain caused by advanced cancer. Characteristics of cancer patients included in the study; Conflict between data from the study and beliefs about morphine-caused constipation.
- Published
- 1999
- Full Text
- View/download PDF
4. Mechanisms of Cancer-induced Bone Pain
- Author
-
Middlemiss, T., Laird, B.J.A., and Fallon, M.T.
- Subjects
- *
BONE physiology , *CANCER pain , *NERVOUS system , *PROSTAGLANDINS - Abstract
Abstract: Cancer-induced bone pain (CIBP) is common and challenging to treat. Common therapies, such as opioids, radiotherapy and bisphosphonates, are often only partially effective. CIBP is a different entity to inflammatory or neuropathic pain and needs to be considered as such. This overview examines the mechanisms of CIBP; the imbalance of bone turnover, peripheral and central nervous involvement and key neurochemical mediators. The current understanding of the underlying pathophysiology of CIBP is discussed. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
5. Predicting Response to Radiotherapy in Cancer-Induced Bone Pain: Cytokines as a Potential Biomarker?
- Author
-
MacLeod, K., Laird, B.J.A., Carragher, N.O., Hoskin, P., Fallon, M.T., and Sande, T.A.
- Subjects
- *
CANCER pain treatment , *ANALGESICS , *BIOMARKERS , *BONE metastasis , *CANCER pain , *CYTOKINES , *RADIOTHERAPY , *RESEARCH , *PAIN management - Abstract
Radiotherapy (XRT) for cancer-induced bone pain (CIBP) has varying levels of efficacy. A biomarker that predicts likely efficacy could stratify XRT to those most likely to benefit. No biomarker is used in clinical practice, but potential candidate cytokines have been identified. The aim of the present study was to examine the relationship between candidate cytokines and analgesic response after XRT. An exploratory analysis was undertaken on biobank data from patients who had received single fraction (8 Gy) XRT for CIBP. The biobank data were prospectively collected from multiple centres in the UK as part of a larger clinical trial, which had institutional review board approval and all patients provided written informed consent for the use of their data in future research. Phenotypic data, pain assessments as well as plasma samples were collected at baseline (within the 24 h before the XRT) and at follow-up (4 weeks after XRT). Baseline and follow-up samples were analysed and levels of 16 pre-identified cytokines were compared in patients classified as XRT 'responders' or 'non-responders'. Data from 60 patients were analysed. Insulin-like growth factor binding protein 9 (NOV/CCN3/IGFBP-9) and interleukin-1ß (IL-1ß) were identified as potential predictors of response to XRT. A significant relationship was shown between the response to XRT and the ratio of the median level of NOV/CCN3/IGFBP-9 at baseline:follow-up (P = 0.024). Furthermore, for the patients up to 64 years of age, the median level of NOV/CCN3/IGFBP-9 was significantly different between responders and non-responders (P = 0.047). For IL-1ß, the median level was significantly different between responders and non-responders in patients with breast cancer (P = 0.006). Although the present findings do not identify robust biomarkers, this is the first such study to examine the role of cytokines in predicting response to XRT in patients with CIBP, and studies that build on these findings are encouraged. • No biomarker is used in clinical practice to predict the response to XRT for CIBP. • This analysis examined candidate cytokines identified by a systematic review. • IL-1ß and NOV/CCN3/IGFBP-9 both show signals associated with XRT response in CIBP. • The observations are supported by preclinical data in this field. • These cytokines need to be validated in larger studies. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
6. Prediction of 90 Day and Overall Survival after Chemoradiotherapy for Lung Cancer: Role of Performance Status and Body Composition.
- Author
-
Bowden, J.C.S., Williams, L.J., Simms, A., Price, A., Campbell, S., Fallon, M.T., and Fearon, K.C.H.
- Abstract
Aims If appropriate patients are to be selected for lung cancer treatment, an understanding of who is most at risk of adverse outcomes after treatment is needed. The aim of the present study was to identify predictive factors for 30 and 90 day mortality after chemoradiotherapy (CRT), and factors that were prognostic for overall survival. Materials and methods A retrospective cohort study of 194 patients with lung cancer who had undergone CRT in South East Scotland from 2008 to 2010 was undertaken. Gender, age, cancer characteristics, weight loss, body mass index (BMI), performance status (Eastern Cooperative Oncology Group; ECOG) and computed tomography-derived body composition variables were examined for prognostic significance using Cox's proportional hazards model and logistic regression. Results The median overall survival was 19 months (95% confidence interval 16.3, 21.7). Four of 194 patients died within 30 days of treatment completion, for which there were no independent predictive variables; 22/194 (11%) died within 90 days of treatment completion. BMI < 20 and ECOG performance status ≥2 were independent predictors of death within 90 days of treatment completion ( P = 0.001 and P = 0.004, respectively). Patients with either BMI < 20 or ECOG performance status ≥ 2 had an odds ratio of death within 90 days of 5.97 (95% confidence interval 2.20, 16.19), rising to an odds ratio of 13.27 (1.70, 103.47) for patients with both BMI < 20 and ECOG performance status ≥ 2. Patients with low muscle attenuation had significantly reduced overall survival ( P = 0.004); individuals with low muscle attenuation had a median survival of 15.2 months (95% confidence interval 12.7, 17.7) compared with 23.0 months (95% confidence interval 18.3, 27.8) for those with high muscle attenuation, equating to a hazard ratio of death of 1.62 (95% confidence interval 1.17, 2.23, P = 0.003). Conclusion Poor performance status, low BMI and low muscle attenuation identify patients at increased risk of premature death after CRT. Risk factors for adverse outcomes should inform personalised discussions with patients about the potential harms as well as the intended benefits of treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.